Contagion Live: Targeting Lung Blood Vessel Inflammation in COVID-19 Patients
UC cardiologist discusses use of razuprotafib to lessen blood vessel inflammation
Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, was interviewed by a reporter for Contagion Live about a new phase 2 clinical trial UC and UC Health are conducting using the drug razuprotafib, to lessen inflammation of the blood vessels in COVID-19 patients. Razuprotafib activates a key pathway for stabilizing blood vessels in the lungs and may prevent or treat respiratory distress in COVID-19 patients. Becker, also a UC Health cardiologist, and Duncan Hite, a professor in the UC College of Medicine, and medical director of critical care at UC Health, are overseeing the trial using razuprotafib at UC. The drug is being used as a part of clinical trial in 20 sites across the nation.
Listen to the Contagion Live interview online.
Learn more about the research involving Dr. Becker and Dr. Hite.
Related Stories
Why jumping spiders mimic wasps
July 25, 2025
In nature's game of survival and attraction, appearances can deceive. University of Cincinnati biologists found that even artificial intelligence mistakes spiders for wasps. The question is why spiders would want to look like their predators.
Student-designed murals bring Bearcat spirit to UC residence...
July 25, 2025
UC transforms campus dorms with vibrant, student-designed murals through the university's nationally ranked co-op program — bringing Bearcat pride and creative energy to residence halls.
UC researchers help create national registry for adaptive...
July 25, 2025
Spectrum News spoke with members of UC's adaptive track and field team, coach Jacob Counts and researcher MeMe Earnest-Stanley about a new national collaboration co-led by UC that is spearheading research and wellness programming with the goal of improving care for adaptive athletes.